Science news

<<  return


HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients

Cholesterol-lowering therapy alone and with blood-pressure (BP)–lowering treatment may prevent CV events in patients considered at "intermediate risk" for CHD—but BP lowering alone doesn"t do the trick unless BP was high to begin with, suggests primary results from the randomized Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial.

At a late-breaking clinical-trial session here at the American College of Cardiology (ACC) 2016 Scientific Sessions, investigators gave three different presentations from HOPE-3, which had a 2x2 factorial design and included almost 13,000 participants without CVD. The findings were simultaneously published  in the New England Journal of Medicine.

It"s interesting that statins are not a new antihypertensive. It very clearly showed that it had no effect on blood pressure—but it stopped the events in the hypertensive people.